FOXO Technologies Inc. (FOXO)
NYSEAMERICAN: FOXO · IEX Real-Time Price · USD
0.234
-0.017 (-6.74%)
At close: Jul 19, 2024, 4:00 PM
0.239
+0.006 (2.40%)
Pre-market: Jul 22, 2024, 7:13 AM EDT

Company Description

FOXO Technologies Inc. develops epigenetic biomarkers technology solutions in the United States.

The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging.

It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers.

FOXO Technologies Inc. was founded in 2020 and is based in Minneapolis, Minnesota.

FOXO Technologies Inc.
FOXO Technologies logo
Country United States
Founded 2019
Industry Health Information Services
Sector Healthcare
Employees 29
CEO Mark Brian White

Contact Details

Address:
729 Washington Ave. N, Suite 600
Minneapolis, Minnesota 55401
United States
Phone (612) 562-9447
Website foxotechnologies.com

Stock Details

Ticker Symbol FOXO
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001812360
ISIN Number US3514713052
Employer ID 85-1050265
SIC Code 8731

Key Executives

Name Position
Mark Brian White Interim Chief Executive Officer and Director
Martin Christopher Ward FCA Interim Chief Financial Officer
Jim Grauel Jr. Chief Distribution Officer
Susan Neo Chief Security Officer

Latest SEC Filings

Date Type Title
Jul 16, 2024 8-K Current Report
Jun 28, 2024 10-Q Quarterly Report
Jun 26, 2024 8-K Current Report
Jun 18, 2024 8-K Current Report
Jun 14, 2024 8-K/A [Amend] Current report
Jun 14, 2024 8-K Current Report
Jun 13, 2024 8-K Current Report
Jun 6, 2024 10-K Annual Report
Jun 4, 2024 10-Q/A [Amend] Quarterly report
Jun 4, 2024 8-K Current Report